Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Losartan

Research Leaders

6 sponsors active, led by The Isaac Foundation

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed1
Unknown1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT01457456Withdrawn

Biomarker for Morquio Disease (BioMorquio)

NCT03632213Phase 2Unknown

Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI

NCT01961518CompletedPrimary

Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome

Showing all 3 trials

Research Network

Common Treatments

  • Losartan1

Active Sponsors

  • The Isaac Foundation1
  • Greenwood Genetic Center1
  • Hospital de Clinicas de Porto Alegre1
  • BioMarin Pharmaceutical1
  • CENTOGENE GmbH Rostock1

Top Investigators

Related Conditions

  • Mps Vi2
  • Morquio Syndrome2
  • Maroteaux Lamy Syndrome1
  • Accumulation Of Mucopolysaccharides1
  • Morquio B Disease1

Activity Timeline